Nephros (NEPH) Expected to Announce Quarterly Earnings on Thursday

Nephros (NASDAQ:NEPH) is anticipated to release its Q3 2025 results before the market opens on Thursday, November 6th. Analysts expect Nephros to post earnings of ($0.02) per share and revenue of $3.8660 million for the quarter. Individuals may review the information on the company’s upcoming Q3 2025 earningreport for the latest details on the call scheduled for Thursday, November 6, 2025 at 4:30 PM ET.

Nephros (NASDAQ:NEPH) last announced its earnings results on Thursday, August 7th. The company reported $0.02 EPS for the quarter, beating analysts’ consensus estimates of ($0.02) by $0.04. The business had revenue of $4.40 million during the quarter, compared to analysts’ expectations of $3.60 million. Nephros had a net margin of 7.95% and a return on equity of 14.89%.

Nephros Stock Down 5.8%

NASDAQ NEPH opened at $5.37 on Tuesday. The stock has a market capitalization of $56.93 million, a P/E ratio of 44.75 and a beta of 1.32. Nephros has a 52-week low of $1.39 and a 52-week high of $5.98. The firm has a 50-day moving average price of $4.69 and a 200 day moving average price of $3.75.

Wall Street Analysts Forecast Growth

NEPH has been the topic of several research reports. Maxim Group increased their price target on shares of Nephros from $4.50 to $6.00 and gave the company a “buy” rating in a research report on Friday, August 8th. Weiss Ratings reaffirmed a “hold (c)” rating on shares of Nephros in a research note on Wednesday, October 8th. Finally, Wall Street Zen raised shares of Nephros to a “strong-buy” rating in a research note on Saturday, October 18th. Two investment analysts have rated the stock with a Buy rating and one has assigned a Hold rating to the company’s stock. Based on data from MarketBeat, Nephros currently has an average rating of “Moderate Buy” and a consensus target price of $5.50.

Hedge Funds Weigh In On Nephros

An institutional investor recently raised its position in Nephros stock. Topline Capital Management LLC boosted its position in shares of Nephros Inc. (NASDAQ:NEPH) by 13.1% in the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 477,449 shares of the company’s stock after purchasing an additional 55,360 shares during the period. Topline Capital Management LLC owned approximately 4.50% of Nephros worth $1,953,000 at the end of the most recent reporting period. 41.10% of the stock is currently owned by institutional investors.

Nephros Company Profile

Nephros, Inc, a commercial-stage company, develops and sells water solutions to the medical and commercial markets in the United States. It offers ultrafiltration products that are used in dialysis centers for the removal of biological contaminants from water and bicarbonate concentrate; and in hospitals for the prevention of infection from waterborne pathogens, such as legionella and pseudomonas, as well as in military and outdoor recreation, commercial, and other healthcare facilities.